OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes
-
Published:2024-01
Issue:
Volume:962
Page:176215
-
ISSN:0014-2999
-
Container-title:European Journal of Pharmacology
-
language:en
-
Short-container-title:European Journal of Pharmacology
Author:
Melander Simone AnnaORCID,
Kayed Ashref,
Andreassen Kim Vietz,
Karsdal Morten Asser,
Henriksen Kim
Reference71 articles.
1. MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study;Ambery;Br. J. Clin. Pharmacol.,2018
2. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis;Armstrong;J. Hepatol.,2016
3. A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway;Bao;Br. J. Pharmacol.,2018
4. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease;Bedossa;Hepatology,2014
5. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients;Bedossa;Hepatology,2012
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献